The patent office in the USA has decided to grant Mologen AG the patent for cell-based gene therapy to treat cancer. This is a significant development for Mologen with respect to the subsequent licensing of a further highly innovative product candidate. Mologen's key technologies Midge and dSLIM and a Mologen cancer cell line are used in the cell-based gene therapy of cancer. Preparations are being made to apply for phase Ib/IIa clinical studies about the cell-based treatment of renal cancer for the product candidate MGN1601.
The process developed by Mologen to treat cancer with cell-based gene therapy involves therapeutic vaccination to combat metastasised tumours and to prevent reoccurrence (recidivation) of them after an operation, radiation and/or chemotherapy.
The clinical application of cell-based gene therapy of renal cancer is being investigated by Mologen as product candidate MGN1601.
Mologen AG, a biopharmaceutical company based in Berlin, specializes in the research and development of innovative medicines based on DNA structures.